Pembrolizumab for patients with PD‑L1-positive advanced gastric cancer (KEYNOTE‑012): a multicentre, open-label, phase 1b trial - Muro, K; Chung, H C; Shankaran, V (Lancet Oncol, 2016)
. doi:10.1016/S1470-2045(16) 00175-3